What is Ligand Pharmaceuticals's D&A?

Ligand Pharmaceuticals (LGND) reported D&A of $8.22M in Q1 2026.

How has Ligand Pharmaceuticals's D&A changed year-over-year?

Ligand Pharmaceuticals's D&A decreased by 6.3% year-over-year, from $8.77M to $8.22M.

What is the long-term trend for Ligand Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), Ligand Pharmaceuticals's D&A has grown at a -9.8% compound annual growth rate (CAGR), from $51.07M to $33.78M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ligand Pharmaceuticals LGND D&A

D&A at other companies

Ionis PharmaceuticalsIONS

$661K+13.6%

Halozyme TherapeuticsHALO

$4.22M+57.1%

Jazz PharmaceuticalsJAZZ

$172.3M+11.6%

RevvityRVTY

——

Roivant SciencesROIV

——

Arrowhead ResearchARWR

——

Segments

By segment

See full

Development and Licensing of Biopharmaceutical Assets$119K-76.8%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's D&A?: Ligand Pharmaceuticals (LGND) reported D&A of $8.22M in Q1 2026.
How has Ligand Pharmaceuticals's D&A changed year-over-year?: Ligand Pharmaceuticals's D&A decreased by 6.3% year-over-year, from $8.77M to $8.22M.
What is the long-term trend for Ligand Pharmaceuticals's D&A?: Over 4 years (2021 to 2025), Ligand Pharmaceuticals's D&A has grown at a -9.8% compound annual growth rate (CAGR), from $51.07M to $33.78M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.